The GLP-1 Cost & Coverage Hub
Insurance denials are the norm, not the exception. This is a working map of every real route — the manufacturers' own pharmacies, the telehealth platforms, and how to put pre-tax HSA or FSA dollars behind any of them.
Prices independently checked 13 September 2026 · no affiliate links · we sell protein, not prescriptions
Start here
Four questions. The answer is a specific place to go, roughly what it costs this month, and the paperwork you need to make it eligible.
Your route
Almost always the cheapest brand-name route, and the least complicated. No subscription fee, no membership, no middleman. Self-pay only — you cannot combine these with insurance.
| Medication | Self-pay per month |
|---|---|
| Zepbound 2.5 mg | $299 |
| Zepbound 5 mg | $399 |
| Zepbound 7.5–15 mg | $449Only if you refill within 45 days. Miss that window and it is $499 at 7.5 mg, $699 at 10–15 mg. |
| Medication | Self-pay per month |
|---|---|
| Wegovy injection, all doses to 2.4 mg | $349$199 for your first two fills if you are new and starting at 0.25 or 0.5 mg — that introductory price runs through 31 December 2026. |
| Wegovy HD 7.2 mg | $399 |
| Wegovy tablets, 1.5 mg | $149The oral ladder climbs: $199 a month at 4 mg, and $299 at 9 mg or 25 mg. |
| Ozempic, doses to 1 mg | $349$499 at the 2 mg maintenance dose. New patients pay $199 for two fills, through 31 December 2026. |
A short note once a month with what actually moved — plus a one-off whenever something real happens, like a new drug clearing approval in the US. No product pitch, no affiliate links, unsubscribe in one click.
Sent by Habthera Nutrition, who publish this page. We don't share or sell your address.
Ranked on total cost to you, transparency of pricing, and how much friction stands between you and an HSA/FSA reimbursement. Our assessment, not a paid placement — we have no commercial relationship with any platform below.
Not a telehealth platform, but it belongs at the top because it beats almost all of them on price. No membership fee layered on the medication. NovoCare takes HSA/FSA cards at the counter. If you already have a prescription, start here and stop.
Wegovy injection around $299/mo, oral Wegovy around $249/mo, Zepbound around $399/mo, with the medication and the visit bundled into one price. Exited compounded semaglutide for new patients in March 2026 after settling with Novo Nordisk, so what you get now is FDA-approved branded product. Bundled pricing is simple to read but harder to itemise for a claim.
Splits the bill: membership is $39 the first month, then $149/mo (about $74/mo paid annually), and the medication is billed separately — Wegovy pen around $199/mo, Zepbound vials around $299/mo, and the oral options around $149/mo at starting doses. Also exited compounded GLP-1s in 2026. The split billing is the reason it ranks here: it is more expensive than it first looks, but it produces cleaner itemised receipts.
Roughly $149–$499/mo depending on the medication and your insurance status. That is an enormous spread, and where you land inside it is not obvious until you are well into the intake. Coaching and behaviour-change support are the differentiator rather than price.
Offers both branded and compounded options, with pricing that varies by medication, formulation and plan tier. That flexibility is genuinely useful for some people and makes an apples-to-apples comparison almost impossible for everyone else. Ask for the all-in monthly number in writing before you commit.
A GLP-1 prescribed for a diagnosed condition is generally an eligible medical expense. Pre-tax dollars stretch roughly 30–40% further than post-tax ones, depending on your tax rate. Here is what governs the money.
| 2026 figure | Amount |
|---|---|
| HSA maximum, individual | $4,400 |
| HSA maximum, family | $8,750Add $1,000 if you are 55 or older and not on Medicare. |
| Health FSA maximum | $3,400 |
| Maximum FSA carryover | $680Your plan offers a carryover or a grace period of 2½ months — never both, and some offer neither. |
Two things are worth knowing that most people miss. First, the telehealth consultation fee is eligible too, not just the medication. Second, what makes a claim stick is documentation: your prescriber should have a qualifying diagnosis in the chart — obesity or type 2 diabetes, coded — rather than a note that says you wanted to lose weight. For products that are not prescriptions, such as nutrition and supplements, the equivalent document is a Letter of Medical Necessity.
Plenty of people weigh this up and go the unregulated route with their eyes open, usually because of price. We are not going to lecture anybody about that. But the two things are not the same product, and it is worth knowing exactly what the trade is before you make it.
A real intake, a real prescriber, and a name you can look up. Not a form that ends in a checkout.
In its original manufacturer packaging, with a prescription in your name.
This is the document your plan administrator wants. No receipt, no reimbursement — however eligible the expense was.
Research-use-only material is not a cheaper version of the approved drug. It is a different product held to a different standard, and independent purity testing has fallen sharply as that market has grown — so in practice nobody can tell you what is in a given vial, including the seller.
The manufacturers set the floor for brand-name product. Well under it means you are buying something else, whatever the label says.
The practical cost is that there is nobody to call if something goes wrong, and no paperwork your plan administrator would accept.
The pills arrived, the compounding era ended, and the muscle question got a more precise answer — not a reassuring one.
The FDA approved oral semaglutide (Wegovy in pill form) in late December 2025, and Novo Nordisk launched it in the US in January 2026. The 1.5 mg starting dose runs about $149/month through savings offers. In trials the 25 mg dose produced average weight loss of about 16.6% at 64 weeks. For anyone who has been putting this off because of needles, that objection is gone.
The first oral non-peptide GLP-1, and notably one you can take without the fasting and water restrictions oral semaglutide requires. Commercial supply for obesity is expected in pharmacies in Q4 2026. Pricing has not been announced — if it follows the usual pattern the list price will be four figures before insurance, which makes the self-pay programme the number to watch, not the list price.
Research presented at the European Congress on Obesity in May 2026 — a retrospective cohort of 486 patients, 82% of them on semaglutide — found fat mass down a mean 18% against skeletal muscle down a mean 5%, with relative muscle mass preserved or increased in more than 70% of them. A 2026 Cell Reports Medicine paper reached a similar conclusion in mice and humans: absolute lean mass falls, but relative muscle mass and strength improve.
Here is the asterisk, and it is why two different numbers circulate. The older figure — that roughly a quarter to two-fifths of the weight lost is lean mass — comes from DEXA sub-studies of the registration trials, and DEXA's “lean mass” counts water, glycogen and organ tissue, not just muscle. Rapid early weight loss sheds a lot of water. So muscle-specific measurements land lower than DEXA does, and both readings can be true of the same person. In the STEP 1 sub-study they were: lean body mass fell 9.7% in absolute terms while rising 3 percentage points as a share of body weight.
None of which means muscle takes care of itself. Absolute lean mass still falls in every one of these studies. And the trial that cut the lean-mass share of weight loss to roughly 7% — BELIEVE phase 2b — did it by adding bimagrumab, an investigational drug that is not approved or available, rather than by leaving things alone. What protects muscle without one is the unglamorous part the same literature keeps agreeing on: resistance training plus roughly 1.2–1.6 g of protein per kg of body weight per day. And involving a registered dietitian has been shown to cut discontinuation rates by 5–10%, which matters, because the drug you stop taking does nothing at all.
The short version of everything above, in the order it actually matters.
Habthera's ASP-1 was formulated by a board-certified physician for people losing weight quickly: 25 g of total protein from whey isolate and collagen, plus creatine, magnesium and methylated B-12. It is HSA/FSA eligible for qualifying customers through Flex, which handles the Letter of Medical Necessity inside checkout in about three minutes.
Shop Habthera on Flex Marketplace → The HSA/FSA Playbook →